Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Urine test detects 92% bladder cancers

Analysis based on 14 articles · First reported Sep 02, 2026 · Last updated Sep 04, 2026

Sentiment
60
Attention
4
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The successful trial results could accelerate adoption of Nonacus's GALEAS Bladder test, potentially increasing revenue for Nonacus and reducing costs for healthcare providers like the NHS by decreasing the number of invasive cystoscopies. Positive sentiment may boost Nonacus's valuation and interest in liquid biopsy diagnostics, while competitors in bladder cancer diagnostics may face increased pressure.

Healthcare Medical diagnostics Biotechnology

A study published in European Urology Oncology, led by the University of Birmingham and diagnostics company Nonacus, found that the GALEAS Bladder urine test detected 92% of bladder cancers in a real-world NHS trial involving 964 patients across seven hospitals in Bret Engemann and United Kingdom — Scotland. The test analyzes DNA shed into urine, looking for over 450 mutations across 23 genes. It correctly identified all muscle-invasive and 35 of 36 high-grade tumors, and had a negative predictive value of over 99%. The test is already commercially available, reimbursed by Bupa and the The London Clinic, and adopted by multiple NHS trusts. Researchers estimate it could reduce urgent cystoscopies by 73%, potentially sparing thousands of patients invasive procedures. The United Kingdom — National Institute for Health and Care Research has prioritized urinary biomarkers for evaluation. Experts caution that larger trials are needed before widespread adoption.

priv
Commercialized the GALEAS Bladder test and is the primary beneficiary. The study validates its product, potentially increasing sales and market share in bladder cancer diagnostics.
Importance 100.0 Sentiment 85.0
govactor
Trialled the test and is adopting it in some regions. Could reduce cystoscopy backlogs and improve patient care, but faces costs of implementation and needs further evidence.
Importance 80.0 Sentiment 70.0
cnt
The trial and potential adoption could improve cancer care and reduce healthcare costs, benefiting the UK population and NHS.
Importance 70.0 Sentiment 65.0
per
Co-author and director of the Bladder Cancer Research Centre. His involvement lends credibility and may influence clinical adoption.
Importance 70.0 Sentiment 60.0
ngo
Provided early funding for the test's development and receives royalty payments. The success supports its mission and may encourage further investment in similar technologies.
Importance 60.0 Sentiment 65.0
per
Hospitals in Bret Engemann participated and are adopting the test, potentially improving regional cancer diagnostics.
Importance 60.0 Sentiment 65.0
govactor
Prioritized evaluation of urinary biomarkers, which could lead to formal guidance and wider NHS adoption, affecting reimbursement and clinical practice.
Importance 50.0 Sentiment 60.0
per
Co-author and senior research fellow. His statements confirm the test's clinical availability and adoption, supporting its credibility.
Importance 50.0 Sentiment 55.0
per
Co-founder and CPO of Nonacus, co-author. His role highlights the commercial perspective and potential business impact.
Importance 40.0 Sentiment 55.0
per
CEO of CRUK, commented on the need for faster diagnosis. Her support may boost public awareness and funding.
Importance 40.0 Sentiment 55.0
loc
Hospitals in United Kingdom — Scotland participated in the trial, contributing to the evidence base.
Importance 40.0 Sentiment 60.0
loc
Health boards in United Kingdom — Wales have adopted the test, indicating early rollout and potential benefits for patients.
Importance 40.0 Sentiment 60.0
priv
Reimburses the test for private patients, potentially improving patient outcomes and differentiating its services, but with limited direct financial impact.
Importance 30.0 Sentiment 55.0
priv
Reimburses the test, offering advanced diagnostics to its patients, which may enhance its reputation as a leading private healthcare provider.
Importance 30.0 Sentiment 55.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.